个人科研网厅 | | 帮助
高级检索
当前位置： 首页 > 详情页

A Phase 1b Study Of Furmonertinib, an Oral, Brain Penetrant, Selective EGFR Inhibitor, in Patients with Advanced NSCLC with EGFR Exon 20 Insertions

| 导出 |

文献详情

资源类型：
WOS体系：

收录情况： ◇ SCIE

作者：
Han, B.[1] * ; Zhou, C.[2] ; Zheng, W.[3] ; Wu, L.[4] ; Ma, Z.[5] ; Wang, H.[5] ; Yu, X.[6] ; Ding, G.[7] ; Ma, D.[8] ; Nie, L.[9] ; Zhang, Z.[10] ; Dong, X.[11] ; Shang, Y.[12] ; Tang, K.[13] ; Zhang, W.[1] ; Hsu, J. Y.[14] ; Jiang, Y.[15] ; Zhao, Q.[15] ;
机构： [1]Shanghai Jiao Tong Univ, Sch Med, Shanghai Chest Hosp, Shanghai, Peoples R China [2]Guangzhou Med Univ, Affiliated Hosp 1, Guangzhou, Peoples R China [3]China Med Univ, ShengJing Hosp, Shenyang, Peoples R China [4]Hunan Canc Hosp, Changsha, Peoples R China [5]Henan Canc Hosp, Zhengzhou, Peoples R China [6]Zhejiang Canc Hosp, Hangzhou, Peoples R China [7]Anqing Municipal Hosp, Anqing, Peoples R China [8]North Sichuan Med Coll, Affiliated Hosp North, Nanchong, Peoples R China [9]Peking Univ First Hosp, Beijing, Peoples R China [10]Anhui Canc Hosp, Baoding, Peoples R China [11]Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Ctr Oncol, Wuhan, Peoples R China [12]Hebei Univ, Affiliated Hosp, Baoding, Peoples R China [13]Sun Yat Sen Univ, Affiliated Hosp 1, Guangzhou, Peoples R China [14]ArriVent Biopharma, Burlingame, CA USA [15]Shanghai Allist Pharmaceut Co Ltd, Shanghai, Peoples R China
出处：
ISSN：

关键词： Non-small cell lung cancer EGFR Exon 20 insertions Furmonertinib

语种：
外文
被引次数：
WOS：
中科院(CAS)分区：
出版当年[2025]版：
大类 | 1 区 医学
小类 | 1 区 肿瘤学 1 区 呼吸系统
最新[2025]版：
大类 | 1 区 医学
小类 | 1 区 肿瘤学 1 区 呼吸系统
JCR分区：
出版当年[2023]版：
Q1 ONCOLOGY Q1 RESPIRATORY SYSTEM
最新[2023]版：
Q1 ONCOLOGY Q1 RESPIRATORY SYSTEM

影响因子： 最新[2023版] 最新五年平均 出版当年[2023版] 出版当年五年平均 出版前一年[2022版]

第一作者：
第一作者机构： [1]Shanghai Jiao Tong Univ, Sch Med, Shanghai Chest Hosp, Shanghai, Peoples R China
推荐引用方式(GB/T 7714)：
Han B.,Zhou C.,Zheng W.,et al.A Phase 1b Study Of Furmonertinib, an Oral, Brain Penetrant, Selective EGFR Inhibitor, in Patients with Advanced NSCLC with EGFR Exon 20 Insertions[J].JOURNAL OF THORACIC ONCOLOGY.2023,18(11):S49-S49.
APA：
Han, B.,Zhou, C.,Zheng, W.,Wu, L.,Ma, Z....&Zhao, Q..(2023).A Phase 1b Study Of Furmonertinib, an Oral, Brain Penetrant, Selective EGFR Inhibitor, in Patients with Advanced NSCLC with EGFR Exon 20 Insertions.JOURNAL OF THORACIC ONCOLOGY,18,(11)
MLA：
Han, B.,et al."A Phase 1b Study Of Furmonertinib, an Oral, Brain Penetrant, Selective EGFR Inhibitor, in Patients with Advanced NSCLC with EGFR Exon 20 Insertions".JOURNAL OF THORACIC ONCOLOGY 18..11(2023):S49-S49

相关文献

[1]Transformation from non-small cell lung cancer to small cell lung cancer: A report of clinicopathological characteristics and prognoses. [2]Furmonertinib versus gefitinib in treatment-naive EGFR mutated non-small cell lung cancer: A randomized, double-blind, multi-center, phase III study (FURLONG) [3]miR-374a-5p inhibits non-small cell lung cancer cell proliferation and migration via targeting NCK1 [4]Characterization of non-small cell lung cancer transforming to small cell lung cancer and its response to EGFR-TKI: a case report [5]Central nervous system efficacy of furmonertinib versus gefitinib in patients with non-small cell lung cancer with epidermal growth factor receptor mutations: Results from FURLONG study [6]lncRNA PDIA3P regulates cell proliferation and invasion in non-small cell lung cancer [7]microRNA-448 inhibits the progression of non-small-cell lung cancer through regulating IRS2 [8]Expert consensus on the diagnosis and treatment of non-small cell lung cancer with MET alteration [9]ISANET: Non-small cell lung cancer classification and detection based on CNN and attention mechanism [10]Delayed cardiotoxicity following osimertinib therapy in non-small cell lung cancer: a unique case report

资源点击量：15100 今日访问量：0 总访问量：960 更新日期：2025-05-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 河北大学附属医院 技术支持：重庆聚合科技有限公司 地址：保定市莲池区裕华东路212号